Looks like production started last week, Phase 111 trials will start next month with the target of 10.000s spread round the World and 500m doses by the end of the year. This is nor what the Western pharma companies wanted to hear.
The Sputnik V, formally named ‘Gam-COVID-Vak’, has already begun production. On Sunday, Gamaleya Institute director Alexander Ginzburg told Sputnik that mass vaccination using the Sputnik V vaccine should start in Russia in about a month’s time.
Russia expects to produce 500 million doses of the vaccine over the next year, with production and clinical trials expected to take place in several other countries as well.
The adenoviral vector vaccine consists of two shots, the second of which is injected three weeks after the first one.
Sputnik V was tested on 76 volunteers at two separate institutions – the Moscow-based Sechenov University and the Russian defence ministry’s Burdenko Main Military Clinical Hospital. Phase III trials involving tens of thousands of volunteers are to be carried out in the coming weeks. More information on the vaccine’s pre-clinical and clinical trials is expected to be published in the coming week to dispel observers’ fears regarding the vaccine’s safety.
Mass vaccination against coronavirus in Russia will start in approximately a month's time, after enough vaccine samples are produced, the director of Gamaleya Research Institute of Epidemiology and Microbiology, Alexander Ginzburg, told Sputnik.
Earlier Ginzburg revealed that the Russian anti-COVID-19 vaccine, dubbed Sputnik V, will undergo post-registration studies, that will take place over the courses of 7-to-10-days. Tens of thousands of people will participate in this research.
"Mass vaccination will be with some delay, only due to the fact that the main part of the produced vaccine will subject to post-registration studies. After that, the rest of the products will be for civilian sales. There will be a delay of 2-3 weeks, maybe a month," the head of the institute explained.
According to the scientist, post-registration studies of the vaccine could take up to six months.
Sputnik V is expected to be produced at two sites - the Gamaleya Research Institute and the company Binnopharm, according to Russian Health Minister Mikhail Murashko.
"The two-stage injection plan helps form a lasting immunity. The experience with vector vaccines and two-stage scheme shows that immunity lasts for up to two years," the Health Ministry earlier said.
The vaccine, which has two separately-injected components, is said to be recommended for individuals aged from 18 to 60 years old. Murashko also said on Friday that Russia will soon release information about the vaccine's pre-clinical and clinical trials to cast away criticism from the international community in regards to an apparent lack of data related to its safety testing.